Horizon Pharma (HZNP) Scheduled to Post Earnings on Monday

Horizon Pharma (NASDAQ:HZNP) will post its quarterly earnings results before the market opens on Monday, February 5th. Analysts expect Horizon Pharma to post earnings of $0.23 per share for the quarter.

Horizon Pharma (NASDAQ:HZNP) last announced its earnings results on Monday, November 6th. The biopharmaceutical company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. The business had revenue of $271.60 million for the quarter, compared to the consensus estimate of $259.74 million. Horizon Pharma had a negative net margin of 45.28% and a positive return on equity of 20.22%. Horizon Pharma’s quarterly revenue was up 30.1% on a year-over-year basis. During the same period last year, the firm posted $0.70 earnings per share. On average, analysts expect Horizon Pharma to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Shares of Horizon Pharma (NASDAQ HZNP) opened at $15.60 on Monday. The firm has a market cap of $2,560.00, a P/E ratio of -5.13, a P/E/G ratio of 0.73 and a beta of 1.30. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.64 and a quick ratio of 1.52. Horizon Pharma has a one year low of $9.45 and a one year high of $17.69.

A number of equities research analysts recently weighed in on the stock. BidaskClub downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Mizuho raised shares of Horizon Pharma from a “neutral” rating to a “buy” rating and raised their target price for the company from $12.00 to $18.00 in a research note on Friday, January 12th. Cantor Fitzgerald set a $17.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Monday, January 8th. ValuEngine downgraded shares of Horizon Pharma from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, UBS Group set a $20.00 target price on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Thursday, November 30th. One research analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $19.25.

TRADEMARK VIOLATION NOTICE: “Horizon Pharma (HZNP) Scheduled to Post Earnings on Monday” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/01/29/horizon-pharma-hznp-scheduled-to-post-earnings-on-monday.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Earnings History for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply